In this week’s edition of InnovationRx, we look at RFK Jr.’s vaccine advisory committee purge, a tech billionaire’s funding ...

Moderna Inc. is in discussions with large drugmakers and financial firms to get funding for some late-stage vaccine trials as ...

An analyst's downbeat new take on Summit Therapeutics ( SMMT -11.32%) pushed its stock downward on Hump Day. At the end of ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

Merck & Co., Inc. (NYSE:MRK) is one of the best wide moat stocks to buy now. On June 9, Merck’s preventative antibody shot ...

The stock's fall snapped a three-day winning streak.

With the U.S. FDA’s approval of Enflonsia (cesrovimab) to prevent respiratory syncytial virus (RSV) infection lower ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Summit Therapeutics (SMMT) stock, a potential rival for Merck (MRK) traded lower as Leerink Partners started its coverage with a Sell-equivalent rating. Read more here.

Hoping to gain an edge in the rapidly growing market are MilliporeSigma and Simtra BioPharma Solutions, which have forged a ...

The world-travelling Curiosity Cube is now in Soweto until the end of June where learners can access fun STEM experiments and ...

The Phase 1 dose escalation has been completed, and results show encouraging early signs of clinical activity in solid tumors with one complete response, one long-lasting partial response, and 11 pati ...